Concepedia

Kanwal Raghav

KR

97

Publications

7.5K

Citations

45

H-Index

2014

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

National Cancer Center Hospital East

University of Milan

Guardant (United States)

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Kanwal Raghav is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and pathology.

ORCID

Top concepts

Publications per year

2014–2025

97

Publications

97

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav et al. · The Lancet Oncology · 2019 · 543 citations

, , +6

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Jonathan M. Loree, Seerat Anand, Arvind Dasari et al. · JAMA Oncology · 2019 · 530 citations · Full text

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

Rachna T. Shroff, Milind Javle, Lianchun Xiao et al. · JAMA Oncology · 2019 · 460 citations · Full text

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. · The Lancet Oncology · 2021 · 392 citations

, , +5

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz, Katherine A. Guthrie, Van K. Morris et al. · Journal of Clinical Oncology · 2020 · 381 citations · Full text

Rows per page

1–5 of 97